Telemark Asset Management LLC Purchases Shares of 400,000 Cellebrite DI Ltd. (NASDAQ:CLBT)

Telemark Asset Management LLC bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 400,000 shares of the company’s stock, valued at approximately $6,736,000. Telemark Asset Management LLC owned 0.19% of Cellebrite DI at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. raised its stake in shares of Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after buying an additional 1,742 shares in the last quarter. Empowered Funds LLC acquired a new position in Cellebrite DI in the third quarter worth about $2,002,000. MQS Management LLC bought a new position in Cellebrite DI during the third quarter worth about $294,000. Venturi Wealth Management LLC lifted its stake in Cellebrite DI by 28.6% during the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after purchasing an additional 2,000 shares during the period. Finally, Meritage Portfolio Management boosted its holdings in Cellebrite DI by 12.0% during the third quarter. Meritage Portfolio Management now owns 27,831 shares of the company’s stock valued at $469,000 after purchasing an additional 2,973 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Ratings Changes

CLBT has been the subject of several analyst reports. Bank of America raised their target price on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Lake Street Capital lifted their price objective on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. TD Cowen boosted their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Craig Hallum boosted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $20.29.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $20.18 on Friday. The stock has a market capitalization of $4.16 billion, a P/E ratio of -13.02, a price-to-earnings-growth ratio of 2.55 and a beta of 1.50. Cellebrite DI Ltd. has a 52 week low of $7.91 and a 52 week high of $21.00. The stock has a fifty day moving average of $17.92 and a 200-day moving average of $14.77.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. During the same period last year, the company earned $0.09 earnings per share. The company’s revenue was up 27.0% on a year-over-year basis. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.